Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp (NASDAQ: KTTA) is a clinical-stage biotechnology company advancing novel therapies for central nervous system disorders and genetic conditions. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress, regulatory milestones, and strategic initiatives.
Our curated collection offers comprehensive tracking of KTTA's developments including clinical trial updates for its lead candidate PAS-004, research collaborations, and advancements in treating conditions like Neurofibromatosis Type 1 and ALS. The content is organized to help stakeholders efficiently monitor the company's progress in neuroscience innovation and drug development.
Key updates cover regulatory filings, partnership announcements, peer-reviewed research publications, and clinical trial results. All content maintains strict editorial standards to ensure accuracy and relevance for both professional investors and those new to biotech equities.
Bookmark this page for centralized access to verified information about Pasithea's therapeutic pipeline, including its work on MEK inhibitors and translational medicine approaches. Check back regularly for essential updates that could impact long-term research trajectories and market positioning.
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
FAQ
What is the current stock price of Pasithea Therapeutics (ktta)?
What is the market cap of Pasithea Therapeutics (ktta)?
